Search the Newsreel

ARWR: Acquires PRV for sNDA Submission for Plozasiran in sHTG

By David Bautz, PhD NASDAQ: ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Acquires PRV to Accelerate sNDA Process for Plozasiran in sHTG On August 4, 2026, Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced it signed an asset purchase agreement with an undisclosed party …

Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher

Arrowhead Pharmaceuticals has acquired an FDA Rare Pediatric Disease Priority Review Voucher to accelerate the review process for its upcoming Supplemental New Drug Application (sNDA) for plozasiran. This sNDA aims to expand the approved indication of plozasiran, currently marketed as REDEMPLO, to include patients …

Bowhead Specialty Holdings Inc. Q2 2026: Revenue $163.9M, EPS $0.48— 10-Q Summary

Bowhead Specialty Holdings Inc. reported strong second-quarter 2026 results, with revenue reaching $163.9M and diluted EPS at $0.48, demonstrating significant year-over-year growth in both top-line performance and underwriting profitability. The company's growth was driven by increased net earned premiums and a strategic shift towards …

Goosehead Insurance (NASDAQ:GSHD) Major Shareholder Sells $6,531,000.00 in Stock

Bowhead Specialty Holdings Inc. reports results for the quarter ended June 30 - Earnings Summary

Bowhead Specialty Holdings Inc. has released its earnings summary for the quarter that concluded on June 30. The full article provides detailed results of the company's financial performance during this period. Readers can access the complete report for further insights.

FDA voucher could put Arrowhead's planned drug filing on a six-month review track

Arrowhead Pharmaceuticals has acquired a Rare Pediatric Disease Priority Review Voucher (PRV) from an undisclosed third party. The company plans to use this voucher to expedite the FDA review of its Supplemental New Drug Application (sNDA) for plozasiran, aimed at treating severe hypertriglyceridemia (sHTG), …

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Announces Quarterly Earnings Results

Arrowhead Pharmaceuticals Q3 Earnings Call Highlights

Arrowhead Pharmaceuticals reported positive Phase III results for plozasiran in severe hypertriglyceridemia (SHTG), leading to plans for a supplemental New Drug Application. The company also highlighted continued growth in its REDEMPLO therapy for familial chylomicronemia syndrome (FCS), with prescription volumes more than doubling. Despite …

Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results

Arrowhead Pharmaceuticals announced its fiscal 2026 third-quarter results, highlighting significant progress in its commercial product REDEMPLO and its robust R&D pipeline. Key achievements include the strong momentum of REDEMPLO's U.S. launch and new marketing authorizations in Europe and Australia, positive topline results for plozasiran …

Goosehead director Peter Lane acquires $101,024 of company stock By Investing.com

Goosehead Insurance director Peter R. Lane purchased 1,600 shares of the company's Class A Common Stock for $101,024 on July 31, 2026. This acquisition aligns with management's aggressive share buyback strategy, as noted by InvestingPro. The news follows Goosehead's strong Q2 earnings, which surpassed …

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - August 3, 2026

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced that its Board of Directors approved inducement grants for 95 new employees on July 16, 2026. These grants, totaling up to 112,794 restricted stock units, fall under NASDAQ Listing Rule 5635(c)(4) and are separate from stockholder-approved equity incentive plans, …

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Bowhead Specialty Holdings Inc. (NYSE: BOW)

Monteverde & Associates PC, an M&A Class Action Firm, has announced an investigation into Bowhead Specialty Holdings Inc. (NYSE: BOW) regarding its sale to American Family Mutual Insurance Company, S.I. Shareholders are expected to receive $34.00 per share in cash, and the firm is …

Bowhead Specialty (NYSE:BOW) Hits New 1-Year High Following Better-Than-Expected Earnings

Goosehead Insurance (GSHD) Posts Strong Earnings And CEO Succession, Is The Stock Fully Valued?

Bowhead Specialty Holdings (BOW) Stock Jumps On Earnings Strength And Valuation Debate

Bowhead Specialty Holdings Inc. (NYSE:BOW) Receives Average Recommendation of "Hold" from Brokerages

Bowhead Specialty Holdings Inc. (NYSE:BOW) has received an average recommendation of "Hold" from brokerages, with six out of nine analysts rating the stock a "hold" and three a "buy." The average 12-month price target is $33.50, notably close to the proposed acquisition price of …

American Family to Acquire Bowhead Specialty Holdings in $1.2 Billion Cash Deal

American Family has agreed to acquire Bowhead Specialty Holdings Inc. (NYSE: BOW) for approximately $1.2 billion in an all-cash deal. This acquisition will bring Bowhead, a specialty insurer known for strong premium growth and underwriting performance, fully under American Family's ownership. The transaction follows …

BOW Stock Alert: Halper Sadeh LLC is Investigating Whether Bowhead Specialty Holdings Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Bowhead Specialty Holdings Inc. (NYSE: BOW) to American Family Mutual Insurance Company, S.I. for $34.00 per share in cash. The investigation aims to determine if Bowhead's board violated federal securities laws …

Bowhead Specialty Holdings Inc. Reports Second Quarter 2026 Results and Cancels Earnings Conference Call Following Announcement of Merger Agreement with American Family

Bowhead Specialty Holdings Inc. (NYSE: BOW) announced its Q2 2026 financial results, which showed a 28.2% increase in gross written premiums and a 30.8% rise in net income. The company also confirmed the cancellation of its earnings conference call following the earlier announcement of …

Bowhead Specialty Agrees to Cash Acquisition by American Family

Bowhead Specialty Holdings Inc. will be acquired by American Family for $34 per share in cash, becoming a wholly-owned subsidiary. The Bowhead board unanimously approved the deal, which is subject to shareholder and regulatory approvals, with a potential $35 million termination fee. The acquisition …

Bowhead Specialty Holdings Inc. (BOW) Reports Q2 Earnings: What Key Metrics Have to Say

Bowhead Specialty Holdings Inc. (BOW) reported its Q2 2026 earnings, with revenues up 23% year-over-year to $163.86 million, and EPS at $0.48. The company's revenue slightly missed the Zacks Consensus Estimate, but EPS surpassed expectations. Key metrics like Expense Ratio and Combined Ratio showed …

Bowhead Specialty (NYSE:BOW) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Earnings To Watch: Bowhead Specialty (BOW) Reports Q2 Results Tomorrow

Bowhead Specialty (NYSE:BOW) Powers Finance Sector Performance Higher Today

Bowhead Specialty (NYSE: BOW) grows premiums, earnings as AmFam deal advances

Bowhead Specialty Holdings Inc. (BOW) Q2 Earnings Top Estimates

The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following Plozasiran’s Phase 3 Success And Zodasiran Milestone

Arrowhead Pharmaceuticals announced positive Phase 3 results for plozasiran in severe hypertriglyceridemia and completed enrollment for the zodasiran Phase 3 trial. These developments bolster the company's cardiometabolic RNAi pipeline, potentially diversifying future revenue and broadening treatment options for lipid disorders. The strong clinical data …

25,200 Shares in Goosehead Insurance $GSHD Bought by Healthcare of Ontario Pension Plan Trust Fund

Vanguard unit discloses 6.38M Arrowhead (ARWR) shares, a 4.53% stake

Vanguard Portfolio Management LLC, along with its affiliates, has reported a beneficial ownership of 6,384,903 shares in Arrowhead Pharmaceuticals Inc. (ARWR), representing a 4.53% stake in the company. This disclosure, filed as a SCHEDULE 13G/A, indicates that Vanguard Portfolio Management has sole voting power …

Bowhead Specialty Holdings Inc expected to post earnings of 47 cents a share - Earnings Preview

Bowhead Specialty Holdings Inc is projected to report earnings of 47 cents per share. This information comes from an earnings preview, indicating financial analysts' expectations for the company's upcoming performance.

Goosehead Insurance (GSHD) director purchases 1,600 shares in open-market trade

Goosehead Insurance, Inc. director Peter R. Lane purchased 1,600 shares of Class A Common Stock on July 31, 2026, at $63.14 per share in an open-market transaction. Following this purchase, he directly holds 1,600 shares. The filing specifies that this trade was not made …

B. Riley Securities Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Raises Target Price to $123

B. Riley Securities has reiterated its Buy rating for Arrowhead Pharmaceuticals (ARWR.US) and increased the price target to $123. This adjustment reflects the firm's continued confidence in the company's financial prospects and market position.

Adrienne Kebodeaux sells 5,000 Goosehead Insurance common shares for $326,000

Adrienne Kebodeaux, a 10% owner of Goosehead Insurance, sold 5,000 Class A shares for $65.2 each, totaling $326,000, on July 28, 2026. This transaction followed a conversion of 5,000 Class B shares to Class A, leaving her with no direct Class A holdings but …

Goosehead Insurance 10% owner trust sells $8.88m in shares

The Mark & Robyn Jones Descendants Trust 2014, a 10% owner of Goosehead Insurance (NASDAQ:GSHD), sold approximately $8.88 million worth of Class A Common Stock across July 29 and 30, 2026. These sales occurred after converting Class B Common Stock and LLC Units into …

Form 4 Goosehead Insurance Inc For: 30 July By Investing.com

This article reports on a Form 4 filing for Goosehead Insurance Inc. for July 30, as released by Investing.com. A Form 4 is a document required by the U.S. Securities and Exchange Commission (SEC) to be filed by company insiders when they buy or …

Adrienne Kebodeaux (GSHD) converts LLC units and sells 5,000 Class A shares

Adrienne Kebodeaux, a 10% owner of Goosehead Insurance (GSHD), converted 5,000 LLC Units and Class B Common Stock into 5,000 Class A Common Stock shares on July 28, 2026. She subsequently sold these 5,000 Class A shares at a weighted average price of $65.20 …